<DOC>
	<DOCNO>NCT01244009</DOCNO>
	<brief_summary>This study investigate efficacy safety MK-4827 participant relapse mantle cell lymphoma ( MCL ) subset participant inactivation Ataxia-Telangiectasia Mutated ( ATM ) gene .</brief_summary>
	<brief_title>A Study MK-4827 Treatment Mantle Cell Lymphoma ( MK-4827-002 )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Niraparib</mesh_term>
	<criteria>Inclusion Criteria : Participant must diagnosis MCL relapse least one prior chemotherapy regimen participant refused standard therapy Participant measureable disease define lymphadenopathy , organomegaly , bone marrow involvement and/or circulate lymphoma cell . At least one lesion must &gt; 2 cm long diameter measurable 2 perpendicular dimension Participant performance status 0 , 1 , 2 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale Female participant childbearing potential agree use two approve contraceptive method remain abstinent throughout study Male participant agree use adequate method contraception throughout study Participant history prior cancer except certain cervical , skin , prostate cancer , undergone potentially curative therapy recurrence five year , deem low risk recurrence Participant platelet red blood cell transfusion colony stimulate factor support month prior treatment Participant prestudy diagnostic formalin fix paraffinembedded tumor tissue sample available Exclusion Criteria : Participant chemotherapy , radiotherapy , biological therapy within 4 week screen Participant history central nervous system ( CNS ) lymphoma Participant require use corticosteroid Participant pregnant , breastfeeding , expect conceive father child study Participant know human immunodeficiency virus ( HIV ) positive Participant history Hepatitis B C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Poly ( ADP-ribose ) polymerase ( PARP ) inhibitor</keyword>
</DOC>